Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftobiprole versus vancomycin plus aztreonam for acute bacterial skin and skin structure infections
2017-001605-32Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute bacterial skin and skin structure infection (ABSSSI) and skin and soft tissue infections (SSTIs) comparing Ceftobiprole arm with Vancomycin plus aztreonam arm (2 arms). Primary endpoint: Investigator-assessed clinical success at test-of-cure. Started Aug 2017; status: completed.
02
Drugs
ceftobiprole medocarilvancomycinaztreonam
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on 2017-001605-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001605-32.